Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
Topical mild steroid + antibacterial + antifungal Pregnancy: Topical administration of corticosteroids to pregnant animals can cause abnormalities of foetal development including cleft palate and intra-uterine growth retardation; the relevance to humans has not been established. However, topical steroids should not be used extensively in the first trimester of pregnancy, and nystatin only with caution. Use of Nystaform HC Cream requires that the anticipated benefits outweigh the possible risks.

Hydrocortisone with chlorhexidine and nystatin

Brand names: Nystaform-HC

Used in: Anaphylaxis & Allergy

This combination preparation pairs the mild corticosteroid hydrocortisone with the antiseptic chlorhexidine and the antifungal nystatin, used for inflammatory skin conditions complicated by candidal and bacterial infection, such as intertrigo and napkin dermatitis.

Adult dose

Dose: Infected skin conditions treated with this mild-corticosteroid / antibacterial / antifungal combination cream — apply to the infected areas 2-3 times daily. Treatment should be for a maximum period of 7 days. §4.2 verbatim: 'Adults and Children: Apply to infected areas 2-3 times daily. Treatment should be for a maximum period of 7 days.' SCOPE: the bundle holds the CREAM formulation; any ointment presentation of this combination has its own SPC and is not sourced here.
Route: Topical. §4.2 Method of administration: 'For topical application only.' §4.4 adds: 'For external use only. Avoid contact with eyes.'
Frequency: 2-3 times daily, for a maximum of 7 days
THE LABEL'S CEILING FOR THIS INDICATION IS A DURATION, NOT A QUANTITY — a maximum treatment period of 7 days. It has deliberately been left in the dose and frequency text rather than written into maxDose, because maxDose is parsed as a quantity and '7 days' would be misread as a numeric dose cap. || The label states no gram-per-application or grams-per-week limit. || WITHDRAWAL (§4.4): long term use of topical steroids can result in rebound flares after stopping (topical steroid withdrawal syndrome) — a severe form can develop as a dermatitis with intense redness, stinging and burning that spreads beyond the initial treatment area, and is more likely when delicate sites such as the face and flexures are treated. If the condition recurs within days to weeks after successful treatment, suspect a withdrawal reaction; reapply with caution and seek specialist advice or consider other treatment options. || 'The label will state mild steroid.' || EXCIPIENTS (§4.4): cetostearyl alcohol may cause local skin reactions (e.g. contact dermatitis); the cream contains 10 mg benzyl alcohol in each gram, which may cause allergic reactions and mild local irritation. || §4.5: 'None stated.'

Paediatric dose

Dose: Children: as for adults — apply to infected areas 2-3 times daily, for a maximum treatment period of 7 days. This is the label's own wording; §4.2 addresses 'Adults and Children' together and gives no separate paediatric figure.
Route: Topical, external use only
Frequency: 2-3 times daily, for a maximum of 7 days
PAEDIATRIC PRECAUTIONS (§4.4): in infants, long-term continuous topical steroid therapy should be avoided — adrenal suppression can occur even without occlusion. As with other topical corticosteroids, systemic absorption may occur when extensive areas are treated, particularly under occlusion. No dosePerKg or concentration is populated: this is a topical preparation applied by area, so there is no per-kilogram figure in the label and none has been invented.

Dose independently re-sourced from UK Summary of Product Characteristics (SPC) via the eMC; US FDA prescribing information (openFDA / DailyMed) — cross-check; US labelling may differ from UK — clinician-reviewed. Always confirm against the product SmPC and your local formulary before prescribing.

Contraindications

  • Tuberculous lesions of the skin
  • Known hypersensitivity to the active substances, especially in those with a history of possible chlorhexidine-related allergic reactions, or to any of the excipients listed in section 6.1
  • Should not be administered to anyone with a potential history of an allergic reaction to a chlorhexidine-containing compound (§4.4)
  • PROVENANCE: §4.3 of the Nystaform HC Cream SPC, complete in the bundle, plus the chlorhexidine exclusion restated in §4.4.

Side effects

  • Frequency not known: allergic skin reactions such as dermatitis, pruritus, erythema, eczema, rash, urticaria, skin irritation and blisters
  • Frequency not known: withdrawal reactions — redness of the skin which may extend to areas beyond the initial affected area, burning or stinging sensation, itch, skin peeling, oozing pustules
  • Frequency not known: hypersensitivity including anaphylactic shock
  • PROVENANCE: §4.8 of the Nystaform HC Cream SPC, complete in the bundle. The label assigns no frequency band other than 'not known' to any of these reactions.

Monitoring

  • Stop treatment at 7 days — the label sets a maximum treatment period of 7 days for this combination
  • If sensitivity occurs, or if a new infection appears, discontinue use and institute alternative therapy
  • Watch for topical steroid withdrawal syndrome if the condition recurs within days to weeks of successful treatment; reapply with caution and consider specialist advice or alternative treatment
  • In infants, avoid long-term continuous topical steroid therapy — adrenal suppression can occur even without occlusion
  • Systemic absorption may occur when extensive areas are treated, particularly under occlusion
  • Avoid contact with the eyes; external use only
  • Chlorhexidine can induce hypersensitivity including generalised allergic reactions and anaphylactic shock — the prevalence is not known but the literature suggests this is likely to be very rare

Clinical monograph

How it works

Hydrocortisone reduces local inflammation via glucocorticoid receptors, chlorhexidine disrupts bacterial cell membranes, and nystatin binds ergosterol to create membrane pores that kill Candida.

Prescribing in practice

  • Reserve the steroid-containing combination for inflamed skin with confirmed or strongly suspected candidal and bacterial involvement, and use short term to avoid steroid-related skin atrophy in flexures and the nappy area.
  • Nystatin treats Candida but is inactive against dermatophytes, so confirm the infecting organism.
  • Avoid on broken skin where chlorhexidine absorption or irritation may be increased.

Monitoring

Review the treated area for resolution of both inflammation and infection and step down the steroid once settled.

Counselling the patient

  • Apply thinly to the affected folds and keep the area clean and dry.
  • Use only for the short period advised, not as a long-term cream.
  • Return if the rash spreads or does not improve.

Evidence & guidelines

Combined topical steroid-antimicrobial products are reserved for inflammatory dermatoses with secondary infection, consistent with standard prescribing references.

Reference: Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. The structured dose values shown have been reviewed by a clinician. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

Calculators
Pathways